» Articles » PMID: 15056653

Solution Structure and Backbone Dynamics of the Non-receptor Protein-tyrosine Kinase-6 Src Homology 2 Domain

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2004 Apr 2
PMID 15056653
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Human protein-tyrosine kinase-6 (PTK6, also known as breast tumor kinase (Brk)) is a member of the non-receptor protein-tyrosine kinase family and is expressed in two-thirds of all breast tumors. To understand the structural basis of PTK6 function, we have determined the solution structure and backbone dynamics of the PTK6-Src homology 2 (SH2) domain using multidimensional NMR spectroscopy. The solution structure clearly indicates that the SH2 domain of human PTK6 contains a consensus alpha/beta-fold and a Tyr(P) peptide binding surface, which are common to other SH2 domains. However, two of the alpha-helices (alphaA and alphaB) are located on opposite faces of the central beta-sheet. In addition, the topological arrangement of a central four-stranded antiparallel beta-sheet (strands betaA, betaB, betaC, and betaD) differs from that of other Src family members. Backbone dynamics and Tyr(P) peptide titration experiments revealed that the putative ligand binding sites of the PTK6-SH2 domain undergo distinctive internal motions when compared with other regions of the protein. Surface plasmon resonance analysis showed that the Tyr(P) peptide had a dissociation constant of about 60 microm, which is substantially weaker binding than previously reported for Src family members. The solution structure together with data from the ligand binding mode of PTK6-SH2 provides insight into the molecular basis of the autoinhibitory role of PTK6.

Citing Articles

In Silico Screening of Multi-Domain Targeted Inhibitors for PTK6: A Strategy Integrating Drug Repurposing and Consensus Docking.

Zhou Y, Wong M Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256893 PMC: 10818313. DOI: 10.3390/ph17010060.


Putting the BRK on breast cancer: From molecular target to therapeutics.

Ang H, Yuan Y, Lai X, Tan T, Wang L, Huang B Theranostics. 2021; 11(3):1115-1128.

PMID: 33391524 PMC: 7738883. DOI: 10.7150/thno.49716.


Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.

Miczi M, Golda M, Kunkli B, Nagy T, Tozser J, Motyan J Int J Mol Sci. 2020; 21(24).

PMID: 33333742 PMC: 7765187. DOI: 10.3390/ijms21249523.


Targeting protein tyrosine kinase 6 in cancer.

Gilic M, Tyner A Biochim Biophys Acta Rev Cancer. 2020; 1874(2):188432.

PMID: 32956764 PMC: 7716696. DOI: 10.1016/j.bbcan.2020.188432.


Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.

Hussain H, Harvey A World J Clin Oncol. 2014; 5(3):299-310.

PMID: 25114846 PMC: 4127602. DOI: 10.5306/wjco.v5.i3.299.